ALK Reports US FDA Approval of Odactra to Treat Children with House Dust Mite Allergy
Shots:
- The US FDA has approved Odactra tablet to treat house dust mite (HDM) induced allergic rhinitis, with or without conjunctivitis, in children (5-11yrs.). Regulatory review in Canada is ongoing
- Approval was based on P-III (MT-12) study assessing Odactra showed significant efficacy & safety in ~1,460 children across North America & EU. Data published in The Lancet Regional Health, Europe
- Additionally, regulatory review for Itulazax (ALK’s tree tablet) for allergic rhinitis in children is ongoing in EU & Canada; expected to complete in 2025
Ref: Globenewswire | Image: ALK
Related News:- Xcovery Holdings Receives US FDA Approval for Ensacove (Ensartinib) to Treat ALK-Positive Locally Advanced or Metastatic NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
